CA2131004A1 - S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component - Google Patents

S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component

Info

Publication number
CA2131004A1
CA2131004A1 CA002131004A CA2131004A CA2131004A1 CA 2131004 A1 CA2131004 A1 CA 2131004A1 CA 002131004 A CA002131004 A CA 002131004A CA 2131004 A CA2131004 A CA 2131004A CA 2131004 A1 CA2131004 A1 CA 2131004A1
Authority
CA
Canada
Prior art keywords
triazine
imidazolyl
substituted
morpholino
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002131004A
Other languages
English (en)
French (fr)
Inventor
Hideshi Kobayashi
Toshihiko Komatsu
Seiichi Fukuda
Yoshio Tsuchida
Masanobu Kato
Shinichi Yaguchi
Naohito Ogose
Hajime Ono
Yasuhiro Izumisawa
Masayuki Takahashi
Tsutomu Nakagane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zenyaku Kogyo KK
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2131004A1 publication Critical patent/CA2131004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002131004A 1992-02-28 1993-02-26 S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component Abandoned CA2131004A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7844992 1992-02-28
JP4-78449 1992-02-28

Publications (1)

Publication Number Publication Date
CA2131004A1 true CA2131004A1 (en) 1993-09-02

Family

ID=13662350

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002131004A Abandoned CA2131004A1 (en) 1992-02-28 1993-02-26 S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component

Country Status (7)

Country Link
US (1) US5489591A (https=)
EP (1) EP0629622B1 (https=)
KR (1) KR950700282A (https=)
AU (1) AU665238B2 (https=)
CA (1) CA2131004A1 (https=)
DE (1) DE69322076D1 (https=)
WO (1) WO1993017009A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
WO1999036410A1 (en) * 1998-01-13 1999-07-22 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
CA2781858C (en) 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
WO2002072561A1 (en) * 2001-01-26 2002-09-19 Smithkline Beecham Corporation Piperazinyltriazines as estrogen receptor modulators
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
CA2503451C (en) * 2002-10-25 2011-07-12 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent comprising the same as effective component
RU2265604C1 (ru) * 2004-09-15 2005-12-10 Кубанский государственный аграрный университет 4,6-бис(морфолил)-2-[(2`-этоксиацетилтетразолил)-5`-ил]-1,3,5-триазин в качестве антидота
WO2006065872A1 (en) * 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
CN101137382B (zh) * 2005-03-11 2012-11-21 全药工业株式会社 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂
US20070244110A1 (en) * 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer
JP2011515462A (ja) * 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
TW200948362A (en) * 2008-04-09 2009-12-01 Mitsubishi Tanabe Pharma Corp New compounds and their uses
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
AR077999A1 (es) * 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
JP6184866B2 (ja) 2010-10-27 2017-08-23 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 新規抗がん剤
SMT202400081T1 (it) 2011-05-03 2024-03-13 Agios Pharmaceuticals Inc Attivatori della piruvato chinasi per uso in terapia
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
PE20142098A1 (es) 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP2906212A4 (en) 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND COMPOSITIONS
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2014287122B9 (en) 2013-07-11 2018-11-01 Les Laboratoires Servier N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
CN105473560B (zh) * 2013-07-11 2020-01-17 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
KR102699521B1 (ko) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
JP7039370B2 (ja) * 2018-04-06 2022-03-22 四国化成工業株式会社 イミダゾリルトリアジン化合物及びその利用
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3308122A (en) * 1965-05-10 1967-03-07 Dow Chemical Co Trimidazolyl triazine compounds
JPS4917677B1 (https=) * 1970-12-30 1974-05-02
JPS5655302A (en) * 1979-10-15 1981-05-15 Hokko Chem Ind Co Ltd Fungicide for agriculture and horticulture
DE3611427A1 (de) * 1986-04-05 1987-10-08 Hoechst Ag Bis-tertiaerbutylamino-substituierte 1,3,5-triazinderivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung

Also Published As

Publication number Publication date
US5489591A (en) 1996-02-06
KR950700282A (ko) 1995-01-16
WO1993017009A1 (fr) 1993-09-02
EP0629622B1 (en) 1998-11-11
EP0629622A4 (https=) 1995-01-18
EP0629622A1 (en) 1994-12-21
AU3575193A (en) 1993-09-13
AU665238B2 (en) 1995-12-21
DE69322076D1 (de) 1998-12-17

Similar Documents

Publication Publication Date Title
CA2131004A1 (en) S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component
JP4276376B2 (ja) 複素環式化合物及びそれを有効成分とする抗腫瘍剤
EP1389617B1 (en) Heterocyclic compound and antitumor agent containing the same as active ingredient
FI114023B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten kinatsolinonien valmistamiseksi
EP1758857B1 (en) Indole derivatives as antiviral agents
Turner et al. Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1, 3, 4-thiadiazoles
OA10946A (en) Substituted 3,5-diphenyl-1,2,4-triazoles and theiruse as pharmaceutical metal chelators
EP0454330A1 (en) Benzimidazolinone derivatives
CZ250995A3 (en) Pyridine derivatives, process of their preparation and intermediates employed in this process as well as pharmaceutical compositions containing thereof
EP2448933B1 (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
CA2194565A1 (en) Anti-helicobacter urea and thiourea derivatives of azolones
AU2003275630A1 (en) Heterocyclic compounds and antitumor agent comprising the same as effective component
JP4709388B2 (ja) 複素環式化合物及びそれを有効成分とする抗腫瘍剤
CA2412216A1 (en) Lactam inhibitors of factor xa and method
JPWO2000043385A1 (ja) 複素環式化合物及びそれを有効成分とする抗腫瘍剤
EP0504574B1 (en) 1,2,4-Oxadiazole derivatives having monoamine oxidase B enzyme-inhibitory activity and method for preparing same
US4247551A (en) N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents
EP0252727A1 (en) Novel amino acid derivatives
EP0009655A1 (en) 6-Amino substituted N-pyrrolyl-3-pyridazine amines, their preparation, and pharmaceutically antihypertensive compositions containing them
EP0510700A2 (en) Azole compounds, their production and use
MXPA04002836A (es) Derivados de alquilaminopiridazinona sustituidos, procedimiento para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
CA2150610C (en) Benzene derivatives and pharmaceutical composition
JPWO1993017009A1 (ja) ｓ−トリアジン誘導体及びそれを有効成分とするエストロジェン依存性疾患治療剤
IE42462B1 (en) 1-methyl-2-nitro-imidazole-5-methanol derivatives
HUT59107A (en) Process for producing new 4(5)-imidazole derivatives having aromatase inhibiting activity and pharmaceutical compositions comprising same as active ingredient

Legal Events

Date Code Title Description
FZDE Discontinued